Go-ahead for LCT
Tuesday, 21 October, 2008
Living Cell Technologies [ASX: LCT] has received approval from the New Zealand Government to conduct a Phase I/IIa clinical trial of DiabeCell.
NZ's Health Minister, David Cunliffe, has approved the company's application, with the project to be monitored by his ministry.
A parallel Phase I/IIa trial commenced in Russia in 2007.
According to LCT, approval from the NZ Government will also make it easier to obtain approvals to trial the product in other companies.
DiabeCell uses insulin-producing porcine islet cells stored within LCT's proprietary encapsulation technology.
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
